Market Place
Sourcing Support
Alligator Bioscience Earnings Call: May 5, 2026
28 Apr 2026 //
PHARMIWEB
Alligator Bioscience Reacts To Henlius` HLX49 Preclinical Data
23 Apr 2026 //
PHARMIWEB
Alligator Bioscience`s Mitazalimab Data To Debut At AACR 2026
20 Apr 2026 //
PHARMIWEB
Alligator Bioscience Provides An Update On Mitazalimab
10 Apr 2026 //
PHARMIWEB
Alligator Bioscience`s Mitazalimab Data To Debut At AACR 2026
18 Mar 2026 //
ACCESSWIRE
Alligator Bio Bolsters Ip Defense For Bispecific Antibody Tech
10 Mar 2026 //
PHARMIWEB
Alligator Comments as Henlius Doses First in Ph2/3
02 Mar 2026 //
PHARMIWEB
Alligator Bioscience AB: Q4 2025 Financial Results & Update
12 Feb 2026 //
PHARMIWEB
Invitation to Alligator Bio`s Earnings Call on 12 February 2026
05 Feb 2026 //
PHARMIWEB
Alligator Bioscience Unveils Mitazalimab OPTIMIZE-1 Data At ASCO
09 Jan 2026 //
PHARMIWEB
Alligator Bio Announces Reactive-2 Phase 1 Trial Data Publication
01 Dec 2025 //
PHARMIWEB
Alligator Bioscience Unveils Mitazalimab & ATOR-4066 Data
05 Nov 2025 //
PHARMIWEB
Alligator Bio Appoints Nomination Committee For AGM 2026
03 Nov 2025 //
PHARMIWEB
Alligator Bioscience AB Reveals Q3 2025 Financials And Update
23 Oct 2025 //
ACCESSWIRE
Alligator Bioscience Secures US Patent For ATOR-4066 Antibody
21 Oct 2025 //
ACCESSWIRE
Alligator Bio To Host Earnings Call On October 23, 2025
16 Oct 2025 //
PHARMIWEB
Mitazalimab Shows Immune Activation In Metastatic Pancreatic
13 Oct 2025 //
ACCESSWIRE
Alligator Publish OPTIMIZE-1 Biomarker Data In Pancreatic Cancer
08 Oct 2025 //
PR NEWSWIRE
Alligator Bio Accepts Two Abstracts At SITC 40Th Annual Meeting
06 Oct 2025 //
ACCESSWIRE
Alligator Reveals Mitazalimab Potential In Metastatic Pancreatic
22 Sep 2025 //
ACCESSWIRE
Alligator Presents New ATOR-4066 Preclinical Results at CICON25
12 Sep 2025 //
ACCESSWIRE
Alligator Publishes Preclinical Data on ATOR-4066 in Cancer
10 Sep 2025 //
ACCESSWIRE
Grant Award for Mitazalimab Ph 2/3 Trial in Biliary Tract Cancer
08 Sep 2025 //
ACCESSWIRE
Alligator Bioscience to Present at BioStock`s Life Science Event
05 Sep 2025 //
ACCESSWIRE
Alligator Bioscience Sets Exercise Price for Warrants Series
27 Aug 2025 //
PHARMAWEB
Alligator Bioscience to present REACtiVe-2 Phase 1 data at ESMO
25 Jul 2025 //
ACCESSWIRE
Alligator to Present 24-Month OPTIMIZE-1 Data at ESMO GI 2025
01 Jul 2025 //
ACCESSWIRE
FDA Endorses Mitazalimab Phase 3 Dose for Pancreatic Cancer
13 Jun 2025 //
ACCESSWIRE
Alligator Bioscience`s OPTIMIZE-1 Trial Biomarker Data at ASCO
03 Jun 2025 //
ACCESSWIRE
Alligator Bioscience Presents Biomarker Data at ASCO 2025 Meeting
23 May 2025 //
ACCESSWIRE
Alligator Bioscience Announces Exercise of Warrants Series TO 12
21 May 2025 //
ACCESSWIRE
Alligator Bioscience Announces Exercise of Warrants Series TO 12
20 May 2025 //
ACCESSWIRE
Alligator: Paediatric Study Waiver for Mitazalimab Granted by EMA
20 May 2025 //
ACCESSWIRE
Alligator Completes Ph3 GMP Manufacturing of Mitazalimab
09 May 2025 //
ACCESSWIRE
Alligator Bioscience Updates Dividend Policy
08 May 2025 //
ACCESSWIRE
Alligator Bioscience AB AGM Bulletin on 7 May 2025
07 May 2025 //
ACCESSWIRE
Alligator Bioscience AB Reports Q1 2025 Financial Results
24 Apr 2025 //
ACCESSWIRE
Alligator Bioscience starts HLX22 Phase 2 trial in breast cancer
23 Apr 2025 //
ACCESSWIRE
Alligator Bio Announces Clinical Development Leadership Transition
21 Mar 2025 //
ACCESSWIRE
Alligator report survival benefit of mitazalimab with mFOLFIRINOX
27 Jan 2025 //
PHARMATIMES
Alligator Doses First Patient in Henlius Phase 3 Trial
04 Dec 2024 //
ACCESSWIRE
Orion and Alligator Bio amend agreement 2 bispecific antibodies
20 Nov 2024 //
PRESS RELEASE
Orion & Alligator Bioscience Amend Bispecific Antibodies Agreement
19 Nov 2024 //
#N/A
Aptevo and Alligator Present Positive ALG.APV-527 Data at SITC 2024
29 Oct 2024 //
ACCESSWIRE
Alligator and Aptevo Announce Positive Data of Dose Escalation Ph of ALG.APV-527
07 Mar 2024 //
ACCESSWIRE
First-line Mitazalimab Plus Chemo Continues to Generate Responses in PDAC
27 Jun 2023 //
ONCOLIVE
Alligator & Aptevo Announce Dosing of First Patient with ALG.APV-527 in PI Trial
13 Feb 2023 //
ACCESSWIRE
